The revenue growth figure is not a typo. Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) generated $1,739,219 in fiscal year 2025, compared to $10,990 in 2024. The increase is attributable to the acquisition of Rocket Doctor Inc., a physician-led digital health platform and marketplace completed in Q2 2025. That acquisition delivered the company’s first meaningful revenue, its first gross margin, and its first operating proof that the physician marketplace model could perform at commercial scale.
For Yazan al Homsi, a cross-border venture capitalist who invested in Rocket Doctor AI through Founders Round Capital, the 2025 results confirm a thesis built not on revenue projections but on the underlying unit economics of the business model. The gross margin, the customer acquisition cost, and the lifetime value ratio were all calculable before the acquisition closed. The 2025 financials confirm those calculations held under real operating conditions.
Why Unit Economics Come Before Revenue
Most digital health investment analyses begin with total addressable market and work backward to a revenue projection. Al Homsi’s approach, shaped by over a decade conducting financial due diligence at PricewaterhouseCoopers in the Middle East, runs the opposite direction. The first question is whether the per-unit economics of the business are defensible. Revenue scale follows from unit economics; it cannot substitute for them.
In Rocket Doctor AI’s case, the unit economics are specific and verifiable. The platform charges an $18 fee per US visit. Customer acquisition costs approximately $5 per patient in the US market. With patients averaging two visits over their initial engagement period, the amortised acquisition cost per visit drops to $2.50. Against an 88% gross margin on each visit, the contribution margin after acquisition costs is approximately $13.34 per US visit.
Over an illustrative two-year patient lifetime, the lifetime value to customer acquisition cost ratio reaches 8.2 times in the US market, indicating the company can profitably spend more on patient acquisition than it currently does, a precondition for the geographic expansion its 2026 roadmap requires. The Canadian market produces a 6.7 times ratio at lower absolute revenue per visit, which explains the deliberate prioritisation of US payer network development over Canadian market deepening.
The Payer Network as a Margin Driver
The 21 million covered lives Rocket Doctor AI now reaches through in-network agreements with major US insurers is not simply a scale metric. Payer integration changes patient acquisition economics in a specific way. Patients accessing the platform through existing insurance coverage face no out-of-pocket cost for the visit, removing the primary friction point in telehealth adoption. Lower friction produces higher conversion rates from platform discovery to completed appointment, reducing the effective cost of patient acquisition without any change to marketing spend.
The company’s 2026 strategy targets high-density payer markets where large covered populations and progressive telehealth reimbursement frameworks can reduce blended customer acquisition costs below their current level. California and New York, where the payer build-out is most advanced, both have regulatory environments that actively support insurance reimbursement for telehealth at parity with in-person care.
Al Homsi’s investment profile across clean technology and healthcare reflects a consistent preference for companies operating in sectors where regulatory tailwinds create structural demand. In telehealth, US reimbursement parity legislation and the expansion of Medicare Advantage into digital health shift the addressable market from optional to default for a large portion of the covered population.
What the 2025 Gross Margin Tells You
Gross margin held between 84% and 89% across all four quarters of 2025, with modest compression in Q4 as patient activity increased and variable costs grew proportionally. The compression from 89% to 84% came from higher variable costs associated with increased patient activity, rather than from fixed cost absorption problems or pricing pressure. A margin structure that compresses modestly under volume growth is fundamentally different from one that deteriorates as scale increases.
For context, Teladoc Health, the largest US telehealth provider, reported gross margins below 70% across most of 2024 and 2025, reflecting the cost burden of its employed clinical staff model and write-downs from its Livongo acquisition. Rocket Doctor AI’s physician marketplace structure avoids the fixed labour cost exposure that has compressed margins across the sector, because clinicians build independent virtual practices on the platform rather than accepting employment contracts.
The Capital Efficiency Argument
The $4.23 million private placement completed in Aug. 2025 was oversubscribed in a year when venture capital deployment in digital health declined sharply from the prior period. Oversubscription in a contraction environment indicates that investors evaluating the company found the unit economics sufficiently compelling to compete for allocation rather than waiting for better terms.
Yazan al Homsi has described his preference for companies that scale without proportional capital requirements. Rocket Doctor AI’s asset-light model expands physician capacity by onboarding clinicians to a marketplace rather than building clinical facilities, which fits that preference directly. The pharmacy kiosk programme, which reached 50 locations in Sept. 2025, generates appointment volume without requiring ownership or lease of physical space. The municipal programme, which established Bruderheim, Alberta as a template for B2G virtual care delivery, provides recurring contract revenue without per-patient acquisition costs.
The combination of payer network access, pharmacy infrastructure, municipal contracts, and direct consumer channels means the company does not depend on any single acquisition pathway to drive visit volume, reducing the unit economics risk that comes from over-reliance on one channel.
Rocket Doctor AI Targets White-Label Deals and Multi-State Payer Expansion Through 2026.
Rocket Doctor AI’s 2026 priorities include multi-state payer expansion, white-label partnerships with US healthcare organisations, continued physician network growth, and the integration of AI automation across intake and documentation processes. The company has approximately 300 clinicians on the platform. Documentation and intake automation is designed to increase the number of visits each physician can complete per day, expanding revenue capacity without proportional clinician recruitment.
For investors tracking Vancouver’s AI investment sector, Rocket Doctor AI’s 2025 results mark the transition from pre-commercial thesis to operating proof. The 15,000% revenue growth is an artefact of the acquisition timing and should be read as a base-establishment event rather than a run-rate indicator. The sustainable signals are the gross margin structure, the payer network build, and the unit economics profile those two factors produce together.
Rocket Doctor AI Inc. trades as CSE: AIDR, OTC: AIRDF, and Frankfurt: 939. Yazan al Homsi is an investor in Rocket Doctor AI and principal of Founders Round Capital (Vancouver) and Catalyst Wire (Dubai).